Objective-A growing body of evidence indicates that platelets contribute to the onset and progression of atherosclerosis by modulating immune responses. We aimed to elucidate the effects of oxidized low-density lipoprotein (OxLDL) on platelet-monocyte interactions and the consequences of these interactions on platelet phagocytosis, chemokine release, monocyte extravasation, and foam cell formation. Approach and Results-Confocal microscopy and flow cytometric analysis revealed that in vitro and in vivo stimulation with OxLDL resulted in rapid formation of platelet-monocyte aggregates, with a preference for CD16+ monocyte subsets. This platelet-monocyte interaction facilitated OxLDL uptake by monocytes, in a process that involved platelet CD36-OxLDL interaction, release of chemokines, such as CXC motif ligand 4, direct platelet-monocyte interaction, and phagocytosis of platelets. Inhibition of cyclooxygenase with acetylsalicylic acid and antagonists of ADP receptors, P2Y1 and P2Y12, partly abrogated OxLDL-induced platelet-monocyte aggregates and platelet-mediated lipid uptake in monocytes. Platelets also enhanced OxLDL-induced monocyte transmigration across an endothelial monolayer via direct interaction with monocytes in a transwell assay. Importantly, in LDLR −/− mice, platelet depletion resulted in a significant decrease of peritoneal macrophage recruitment and foam cell formation in a thioglycollate-elicited peritonitis model. In platelet-depleted wild-type mice, transfusion of ex vivo OxLDL-stimulated platelets induced monocyte extravasation to a higher extent when compared with resting platelets. Conclusions-Our results on OxLDL-mediated platelet-monocyte aggregate formation, which promoted phenotypic changes in monocytes, monocyte extravasation and enhanced foam cell formation in vitro and in vivo, provide a novel mechanism for how platelets potentiate key steps of atherosclerotic plaque development and plaque destabilization. 
A therosclerosis is a chronic inflammatory process that involves a complex interplay of cellular and noncellular components and coincides with abnormal lipid profiles and oxidative stress. The pro-oxidative environment present in atherosclerosis favors the oxidation of low-density lipoprotein (LDL), which can be detected in the blood stream 1, 2 and in atherosclerotic lesions. 3, 4 Extravascular lipid retention is one of the initial steps in atherogenesis. 5, 6 Although the uptake of native lipoproteins is a strictly regulated and saturable process, uptake of oxidized lipoproteins, such as oxidized low-density lipoprotein (OxLDL), by scavenger receptors on macrophages does not involve any negative feedback regulation and thereby results in unlimited uptake, leading to foam cell formation. 5, 7 OxLDL interaction with leukocytes and endothelial cells induces activation and chemokine secretion, favoring leukocyte recruitment, adhesion, and transmigration. 5, 6, 8, 9 Platelets also interact with OxLDL, which results in platelet activation and the release of further atherosclerosis-promoting chemokines and cytokines. 5, 7, [10] [11] [12] Furthermore, platelets internalize OxLDL and these OxLDL-laden platelets can activate the endothelium and can inhibit endothelial regeneration in vitro. 7, 13 Interestingly, increased OxLDL binding to the surface of circulating platelets was recently detected in patients with acute coronary syndrome and correlated with platelet reactivity, 14 suggesting that OxLDL indeed is a relevant in vivo activator of platelets.
Circulating activated platelets further adhere to the endothelium, thereby propagating leukocyte recruitment and extravasation and promoting the development of atherosclerotic lesions via P-selectin-dependent mechanisms. [15] [16] [17] [18] Activated platelets also adhere to circulating leukocytes, and these platelet-leukocyte complexes are a central feature of various inflammatory diseases. 19 In particular, platelet-monocyte aggregates (PMAs) have been shown to be an early predictor for cardiovascular events. 20 In this study, we provide the first evidence that platelets are causally involved in lipid accumulation and in vivo generation of lipid-rich foam cells. Our results indicate a novel mechanism for how platelets contribute to the onset and progression of atherosclerosis and negatively regulate plaque stability.
Materials and Methods
Materials and Methods are available in the online-only Supplement.
Results

In Response to OxLDL Platelets Rapidly Formed Complexes With Monocytes In Vitro and In Vivo
OxLDL interaction with platelets leads to a rapid upregulation of surface P-selectin. 21, 22 Because monocytes constitutively express P-selectin glycoprotein ligand-1 (PSGL-1), OxLDL-stimulated platelets also interacted with monocytes within minutes of activation ( Figure 1A ). As depicted in Figure 1B , the percentage of platelet-monocyte complexes significantly increased with the degree of oxidative modification of LDL, whereas native LDL had no effect on PMA formation. The formation of PMA on OxLDL stimulation was further confirmed by confocal microscopy, which revealed that platelets interacted with OxLDL and bridged monocyte-monocyte contacts ( Figure 1C ). We could further show that platelet-monocyte interactions also occurred in vivo. After intravenous injection of OxLDL into C57BL/6J mice, we detected a significant increase of circulating PMA ( Figure III in the online-only Data Supplement). Characterization of monocyte subsets (shown in Figure IIA in the online-only Data Supplement) revealed that platelets predominantly bound to CD16 + monocytes ( Figure 1D ). The effects of OxLDL on PMA formation were dose dependent and critically mediated by P-selectin because a blocking antibody against P-selectin virtually abrogated OxLDL-induced PMA formation ( Figure 1E ). To determine the contribution of monocyte and platelet activation to PMA formation, either platelets or monocytes were preincubated with OxLDL and then-either after OxLDL removal by washing (as in Figure 1F ) or without washing ( Figure 1G )-incubated with the respective resting cell type. Indeed, we found that the contribution of OxLDL-stimulated platelets to PMA formation was more pronounced when compared with OxLDL stimulation of isolated monocytes ( Figure 1F and 1G Figure 1 . In vitro formation of human platelet-monocyte aggregates (PMA) in response to oxidized low-density lipoprotein (OxLDL). A, PMA formed after stimulation of human white blood cell-enriched whole blood with OxLDL (50 μg/mL) for 5 and 20 minutes. Mean±SD (n=6); **P<0.01. B, PMA formation in human white blood cell-enriched whole blood in response to LDL (50 μg/mL) of different degrees of oxidative modification with hypochlorite/hypochlorous acid (OCl − /HOCl) for 10 minutes; numbers in brackets indicate molar excess of OCl − /HOCl over LDL. Mean±SD (n=6); *P<0.05, **P<0.01. C, Representative immunofluorescent images: human monocytes (red), OxLDL (green), and platelets (blue). Scale bars, 10 μm. D, Analysis of human monocyte subsets of PMA after stimulation with OxLDL (50 μg/mL) for 10 minutes. Mean±SD (n=5); *P<0.05. E, Effect of anti-P-selectin antibody (10 μg/mL) on human PMA formation in white blood cell-enriched whole blood induced by different concentrations of OxLDL (10-200 μg/mL). Mean±SD (n=6); **P<0.01. F and G, Effects of cell-specific OxLDL stimulation on PMA formation. F, Isolated platelets and monocytes were separately stimulated with OxLDL (50 μg/mL) for 10 minutes and, after removal of OxLDL by washing, added to the respective resting cell population for 10 minutes. G, Isolated platelets were stimulated with OxLDL (50 μg/mL) for 10 minutes before reconstitution with resting monocytes (and vice versa) and PMA formation determined after 2 and 5 minutes. White bars, unstimulated cells; black bars, only monocytes were stimulated with OxLDL; gray bars, only platelets were stimulated with OxLDL. Mean±SD (n=5); *P<0.05, ** P<0.01.
These findings demonstrate that platelet activation in response to OxLDL leads to rapid heterotypic aggregate formation preferentially with CD16+ monocytes.
Platelets Enhance OxLDL Uptake by Monocytes Via P-Selectin-PSGL-1 Interaction
Because immunofluorescent staining indicated that OxLDL is predominantly bound by platelets, we speculated that interaction with (lipid-laden) platelets might result in an increased OxLDL uptake by monocytes.
As depicted in Figure 2A , we indeed observed an enhanced uptake of OxLDL by monocytes in the presence of platelets after 1 hour of coincubation. Calculations of the lipid-rich area within monocytes clearly demonstrated that the presence of platelets doubled OxLDL uptake. Flow cytometric analysis revealed that the presence of platelets not only resulted in an increased amount of OxLDL bound and taken up by monocytes but also enhanced the percentage of lipid-laden monocytes in a dose-and time-dependent manner ( Figure 2D and 2E) . The ability of platelets to increase OxLDL binding and uptake in Figure 2 . Effect of platelets, CD36, and scavenger receptor class A (SR-A) on oxidized low-density lipoprotein (OxLDL) uptake by human monocytes. A-E, Effect of platelets on OxLDL accumulation in human monocytes. A, Uptake of Alexa488-labeled OxLDL (green) into monocytes (red) in the absence and presence of platelets after 1 hour as depicted by representative confocal fluorescence images (left) and mean percentage+SD (right); scale bars, 10 μm; (n=5); *P<0.05. B, Representative confocal images of Oil red O positivity of monocytes (green) after 24 hours of cultivation in serum-free medium with OxLDL (20 μg/mL) in the presence and absence of platelets. Scale bars, 10 μm. C, Mean+SD of Oil red O-positive monocytes (black bars) cocultured with platelets (white bars) for 24, 48, and 72 hours (expressed as fold change relative to the lipid uptake in the absence of platelets; n=5); *P<0.05. D, Flow cytometric analysis of the effect of platelets on the uptake of different concentrations of OxLDL (10-160 μg/mL) by monocytes. Mean±SD (n=5); **P<0.01. E, Timecourse of the uptake of Alexa488-labeled OxLDL (50 μg/mL) by monocytes in white blood cell-enriched whole blood in the presence or absence of an anti-P-selectin antibody (10 μg/mL). Mean±SD (n=5); *P<0.05, **P<0.01. F, Role of P-selectin, CD36, and SR-A on the platelet-mediated uptake of OxLDL by monocytes in human white blood cell-enriched whole blood after 1 hour at 37°C. CD36 was blocked by FA6.152 (4 μg/mL) and SR-A was blocked by fucoidan (50 μg/mL) with or without anti-P-selectin antibody (10 μg/mL). Final concentration of OxLDL, 50 μg/mL. Mean±SD (n=5); **P<0.01.
monocytes was dose dependent with statistical significance at concentrations between 40 and 80 μg/mL, whereas at high concentrations of OxLDL (160 μg/mL) platelets were unable to enhance OxLDL uptake by monocytes further, probably because of saturation of OxLDL binding/uptake by monocytes. As shown in Figure 2E , inhibition of P-selectin-PSGL-1 interaction with a blocking anti-P-selectin antibody significantly reduced OxLDL binding/uptake by monocytes for a period of 2 hours, indicating that PMA formation is necessary for this process. Cocultivation of monocytes and platelets increased lipid accumulation in monocytes also at longer time periods. Quantification of Oil red O-positive lipid droplets revealed a significant increase in lipid uptake by ≈80% after 24 hours of monocyte cultivation with platelets, which reflects a 1.8-fold increase when compared with monocultures ( Figure 2B and 2C). In the absence of platelets, lipid accumulation still increased after 48 and 72 hours, whereas no significant changes in lipid uptake could be observed in platelet-monocyte cocultures between 48 and 72 hours ( Figure 2C ).
These results indicate that platelets accelerate lipid accumulation and thereby potentially enhance foam cell formation. We then aimed to determine the role of scavenger receptor CD36, scavenger receptor class A (SR-A), and toll-like receptor 4 (TLR4) for platelet-mediated uptake of OxLDL. CD36 is the major receptor for OxLDL on platelets, 23, 24 but both CD36 and SR-A have been shown to be important for foam cell formation. 25, 26 Depending on the type of (oxidatively) modified LDL, also TLR4 has been demonstrated to be involved in lipid accumulation by monocytes/macrophages through Syk-dependent mechanisms. 27 To determine the contribution of CD36 and SR-A to monocyte OxLDL uptake in whole blood, we inhibited CD36 with FA6.152, an antibody that specifically blocks binding of OxLDL to CD36, and inhibited SR-A by fucoidan. To determine the contribution of direct platelet-monocyte interaction to platelet-mediated OxLDL uptake by monocytes, we blocked P-selectin-PSGL-1 binding in addition to scavenger receptor inhibition ( Figure 2F ). Consistent with our findings shown in Figure 2E , blockade of P-selectin significantly decreased OxLDL uptake by ≈40%. Blocking CD36 reduced the uptake of OxLDL by monocytes to a comparable extent, whereas a cocktail of both anti-P-selectin and FA6.152 had no additional effect. However, the combined inhibition of CD36 and SR-A resulted in a significantly stronger decrease in OxLDL uptake when compared with P-selectin blockade alone ( Figure 2F ). Of note, in our experimental setting, specific blockade of TLR4 had no effect on OxLDL-induced PMA formation ( Figure IVA These findings indicate an important role of CD36 in platelet-mediated uptake of OxLDL by monocytes and reveal a central role for SR-A in direct uptake of OxLDL by monocytes.
Phagocytosis of Platelets and PlateletDerived CXC Motif Ligand 4 Contribute to OxLDL Uptake by Monocytes
To elucidate whether phagocytosis of platelets is the underlying mechanism for platelet-mediated OxLDL uptake in monocytes, we labeled platelets with Cell Tracker green and determined whether they were internalized or remained surface bound in response to OxLDL stimulation.
We found that after 1 hour of OxLDL stimulation, ≈20% of platelets were internalized by monocytes ( Figure 3A) , which was confirmed by confocal microscopy as depicted in Figure 3A (top). Phagocytosis of platelets was verified by coincubation of pHrodo-labeled platelets (red) and monocytes (green) further ( Figure 3A, bottom) .
Platelet release of soluble mediators, such as CXC motif ligand 4 (CXCL4; platelet factor 4), is known to modulate platelet-monocyte crosstalk and monocyte functions. 16, 28 On activation with different concentrations of OxLDL, platelets released CXCL4 in a dose-dependent manner ranging between 4 and 8 μg/mL per 10 9 platelets ( Figure 3B ). We tested whether platelet supernatant itself can mimic the effects of platelets on OxLDL uptake by monocytes. As depicted in Figure 3C , supernatants of activated platelets showed a tendency to enhance OxLDL uptake by monocytes, which could be counteracted by heparin and blocking CXCL4. As shown in Figure 3D , inhibition of CXCL4 in whole blood by heparin or a CXCL4 blocking antibody decreased OxLDL uptake by monocytes, which could be further reduced by blockade of P-selectin. Of note, already at a 1/10 dilution of platelet supernatant the observed amplifying effect vanished (data not shown), indicating that in circulation CXCL4 is likely to act only locally on monocytes, which implies that direct cell-cell contact is indispensable.
Acetylsalicylic Acid Decreases PMA Formation and Platelet-Mediated OxLDL Uptake
We next tested the efficiency of acetylsalicylic acid (ASA) in counteracting OxLDL-induced PMA formation, monocyte activation, and OxLDL uptake. As shown in Figure 4A , in whole blood ASA dose dependently decreased OxLDL-induced PMA formation, which reached statistical significance at concentrations of 1 μg/mL and higher. Interestingly, ASA treatment was unable to decrease OxLDL-mediated CD11b activation on isolated monocytes ( Figure 4B ). In line with these results we found that ASA significantly decreased OxLDL uptake in whole blood but had no effect on OxLDL uptake by isolated monocytes ( Figure 4C ). However, ASA was less efficient in blocking the platelet-mediated OxLDL uptake by monocytes when compared with anti-P-selectin, neither could a combination of ASA and anti P-selectin further abrogate OxLDL uptake by monocytes in whole blood. Of note, the anti-P-selectin antibody did not interfere with OxLDL uptake by isolated monocytes, thereby ruling out any platelet-unrelated effects of anti-P-selectin on OxLDL uptake ( Figure 4C ).
The Role of P2Y1 and P2Y12 Receptors in OxLDLInduced PMA Formation and OxLDL Uptake
We then determined whether inhibitors of purinergic receptors, P2Y12 (MRS2159 and ticagrelor) and P2Y1 (MRS2179), could antagonize OxLDL-mediated platelet-monocyte interactions and subsequent OxLDL uptake. As depicted in Figure 5A , P2Y1 inhibition either alone or together with the P2Y12 inhibitor MRS2159 (applied at the most effective dose of 10 μmol/L; Figure VA and VC in the online-only Data Supplement) significantly reduced OxLDL-induced PMA formation in whole blood, whereas the P2Y12 antagonist showed only a tendency to inhibit platelet-monocyte interactions in response to OxLDL. In vivo relevant concentrations of ticagrelor had similar effects on OxLDL-induced PMA formation when compared with MRS2159 ( Figure VB in the online-only Data Supplement). Similar to ASA, blockade of ADP receptors was without any significant effect on CD11b activation on isolated monocytes in response to OxLDL ( Figure 5B ). However, ADP receptor antagonists significantly reduced OxLDL uptake by monocytes in whole blood but were less efficient than anti-P-selectin. Moreover, a combination of P2Y inhibitors and anti-P-selectin had no additive effect, indicating that P2Y inhibitors only interfered with platelet-mediated effects on OxLDL uptake by monocytes. This hypothesis was further confirmed by the finding that OxLDL uptake by isolated monocytes remained unaffected in the presence of ADP receptor antagonists ( Figure 5C ).
Platelets Potentiate Monocyte Extravasation and Foam Cell Formation in Response to OxLDL In Vitro and In Vivo
We further found a significant increase in OxLDL-induced monocyte CD11b activation (reflected by induction of neoepitope CBRM1/5) in the presence of platelets ( Figure 6A ), whereas total CD11b remained unchanged at 10 minutes after OxLDL stimulation ( Figure VIA in the online-only Data Supplement). This demonstrates that platelets further enhance the adhesive and migratory capacity of monocytes. In line with these observations, we found that incubation of whole blood with an anti-P-selectin antibody abrogated platelet-mediated monocyte CD11b activation, indicating that direct interactions between platelets and monocytes are necessary for the observed effects ( Figure VIB in the online-only Data Supplement).
A transwell-migration assay further revealed that platelets significantly enhanced transmigration of monocytes across a human umbilical vein endothelial cell monolayer in response to OxLDL ( Figure 6B ). However, in the presence of anti-P-selectin, the percentage of transmigrated monocytes was significantly reduced and platelet-mediated increase in monocyte transmigration could no longer be observed. Pretreatment with ASA or blockade of OxLDL binding to CD36 also showed a tendency to decrease OxLDL-induced monocyte transmigration ( Figure 6B ).
We then determined whether platelets are also able to enhance monocyte extravasation in vivo in a thioglycollate-elicited sterile peritonitis model with platelet-depleted LDLR −/− mice. . B, Levels of CXCL4 released by platelets (1×10 9 /mL) on stimulation with different concentrations of OxLDL (20-80 μg/mL) for 10 minutes as measured by ELISA. Mean±SD (n=4); **P<0.01. C, Effects of heparin (2 U/mL) and anti-CXCL4 antibody (1.75 μg/mL) on OxLDL uptake by monocytes in the presence of platelet-free supernatant after 1 hour. Mean±SD (n=5). D, Role of heparin (2 U/mL), CXCL4 antibody (1.75 μg/mL), and anti-P-selectin (10 μg/mL) on platelet-mediated uptake of OxLDL (50 μg/mL) by monocytes in human white blood cell-enriched whole blood after 1 hour. Mean±SD (n=5); *P<0.05, **P<0.01.
Platelet depletion with R300, an anti-CD42b antibody, led to an ≈80% reduction in platelet count, whereas no differences in other blood parameters, such as the total white blood cell count, number of lymphocytes, neutrophils, or monocytes, could be observed (Table I in the online-only Data Supplement). Platelet depletion led to a dramatic decrease of peritoneal macrophages in LDLR −/− mice after 72 hours of thioglycollate stimulation ( Figure 6C) . Notably, recruitment of neutrophils was also decreased in plateletdepleted LDLR −/− mice ( Figure VII in the online-only Data Supplement). As depicted in Figure 6D by representative flow cytometric dot plots, platelet depletion resulted in a considerably reduced number of recruited peritoneal macrophages when compared with control mice, whereas resident Tim-4 and 12/15-lipoxygenase coexpressing macrophages in the peritoneal cavity remained rather unchanged ( Figure 6E ). As depicted in Figure 6F , the observed effects are not limited to LDLR −/− mice because platelet transfusion of ex vivo OxLDLstimulated but not unstimulated platelets, resulting in ≈50% increase in platelet count, was able to increase the number of peritoneal macrophages in platelet-depleted C57BL/6J mice. μg/mL) on OxLDL-induced PMA formation in human white blood cell-enriched whole blood. Mean±SD (n=6); **P<0.01. B, Influence of ASA (0.1-10 μg/mL) on CD11b activation on isolated monocytes stimulated with OxLDL (50 μg/mL) for 10 minutes. Mean±SD (n=6). C, Effect of ASA (10 μg/mL) and anti-P-selectin antibody (10 μg/mL) on the uptake of OxLDL (50 μg/mL) by monocytes in human white blood cell-enriched whole blood (black bars) or by isolated monocytes (gray bars) after 1 hour. Mean±SD (n=5); *P<0.05, **P<0.01. Figure 5 . Role of purinergic receptors, P2Y1 and P2Y12, on oxidized low-density lipoprotein (OxLDL)-induced platelet--monocyte aggregate (PMA) formation, monocyte CD11b activation, and OxLDL uptake. A and B, Effect of P2Y12 receptor inhibitor MRS2159 (10 μmol/L) and P2Y1 receptor inhibitor MRS2179 (10 μmol/L) on PMA formation in human white blood cell-enriched whole blood (A) and monocyte CD11b activation on isolated monocytes (B) in response to stimulation with OxLDL (50 μg/mL) for 10 minutes. Mean±SD (n=6); **P<0.01. C, Effect of anti P-selectin antibody (10 μg/mL) and P2Y12 and P2Y1 inhibitor (10 μmol/L) on the OxLDL uptake by monocytes in human white blood cell-enriched whole blood (black bars) or by isolated monocytes (gray bars) after 1 hour. Final concentration of OxLDL, 50 μg/mL. Mean±SD (n=5); *P<0.05, **P<0.01.
To evaluate the effect of platelets on the formation of foam cells in vivo further, we analyzed the lipid accumulation in thioglycollate-elicited peritoneal macrophages in platelet-depleted LDLR −/− mice. Platelet depletion decreased the percentage of foam cells by ≈50% ( Figure 6G ). Moreover, Oil red O positivity was generally less pronounced in platelet-depleted LDLR −/− mice ( Figure 6G ). From these results, we conclude that platelets are not only able to accelerate lipid accumulation in vitro but also promote foam cell formation in vivo.
Discussion
Here, we show that platelets play an important role in monocyte extravasation and lipid accumulation in response to OxLDL. OxLDL rapidly triggered PMA formation in vitro and in vivo. The observed effects of OxLDL on platelet-monocyte interactions were dependent on the concentration and the degree of oxidative modification of LDL. Although platelet-monocyte interactions involve a variety of receptor-counter-receptor pairs, such as CD147/basigin or CD11b/CD18-glycoprotein Ib α (GPIbα), 29, 30 and are also modulated by secreted soluble mediators, such as CXC motif ligand 16 (CXCL16) or CX3-C motif ligand 1 (CX3CL1), 31, 32 our findings reinforce P-selectin as the key initial mediator for platelet-leukocyte interactions because blocking P-selectin-PSGL-1 interactions virtually abrogated platelet interaction with monocytes. P-selectin has previously been shown to be involved in the development and exacerbation of atherosclerotic lesions by bridging platelets to leukocytes.
16,33,34 P-selectin also initiates transient platelet interactions with the endothelium 35 or monocytes 16 and thereby mediates endothelial deposition of plateletderived soluble mediators, such as C-C motif ligand 5 17, 18 and contact-mediated deposition of C-C motif ligand 5 or CXCL4 on the surface of monocytes. 16 Interestingly, recent results from preclinical and clinical studies suggest that administration of a novel anti-P-selectin antibody suppresses plateletleukocyte interactions and represents a promising approach to target the early onset and progression of atherosclerosis. 36 We further found that platelets preferably bound to the nonclassical and intermediate monocyte subsets and also observed a shift toward CD16 + monocytes in the presence of platelets and OxLDL. These observations are in line with previous reports, showing P-selectin-PSGL-1 interactions to be sufficient to trigger phenotypic changes toward proinflammatory CD16 + monocytes, which lead to increased endothelial adhesiveness. 37, 38 Although platelet-leukocyte interactions are known to result in mutual activation, we found platelet activation to be more important for PMA formation when compared with monocyte activation. These observations are in line with results from a recent study, showing that in response to thrombin activated platelets, not thrombin itself, trigger early signaling events (such as intracellular Ca ++ flux) in monocytes on platelet-monocyte interaction. 39 Platelet interaction with monocytes via P-selectin-PSGL-1 further increased the rate and quantity of OxLDL uptake by monocytes in a dose-dependent manner. Scavenger receptor CD36, the major receptor for OxLDL on platelets, 23, 24 was mainly responsible for the platelet-mediated effects on OxLDL uptake by monocytes. On macrophages, the principal receptors responsible for OxLDL uptake and subsequent foam cell formation are CD36, SR-A, and TLR4. 25, 27, 40, 41 In blood-derived monocytes, SR-A was crucially important for the direct interaction of monocytes with OxLDL, whereas in our setting TLR4 did not play a major role in OxLDL uptake by monocytes, and CD36 was only involved in platelet-mediated effects of OxLDL uptake. It has been reported that fucoidan not only inhibits binding of OxLDL to SR-A 42 but also interferes with P-and L-selectins, 43, 44 which might explain the almost complete prevention of OxLDL uptake by monocytes in response to fucoidan. Platelet-mediated effects on OxLDL uptake by monocytes were partly mediated by internalization of platelets. In macrophages, phagocytosis of lipid-laden platelets has been previously shown to play a role in foam cell formation 45 and activated platelets were demonstrated to propagate lipid accumulation in CD34 + cells. 13 However, in monocytes phagocytosis of platelets does not seem to be the major mechanism for OxLDL uptake because only a small percentage of platelets was internalized by monocytes.
Several cytokines released by activated platelets have been demonstrated to modulate monocyte and macrophage function. 16, 38, 46 The most abundant platelet chemokine CXCL4 was shown to induce phenotypic changes in macrophages, resulting in an increased proatherogenic potential by making them more susceptible to foam cell formation. 28, [47] [48] [49] In response to OxLDL stimulation, platelets released CXCL4 and the supernatant of OxLDL activated platelets could partly mimic the observed effects of platelets on lipid uptake by monocytes. A CXCL4 neutralizing antibody and heparin counteracted the platelet-mediated effects on monocytes. Of note, undiluted platelet supernatant was necessary for the observed effects, indicating that in circulation CXCL4 is likely to act only locally on monocytes, which implies that direct cellcell contact is essential. In the blood stream, in particular, where secreted mediators are rapidly diluted or cleared, platelet contact-mediated deposition of CXCL4, as well as C-C motif ligand 5 on the endothelium, 17, 18 and on the surface of monocytes 16 is important for monocyte activation, adhesion, and migration. Our results indicate a potent role for CXCL4 released by OxLDL activated platelets in lipid uptake by monocytes and subsequent atherogenic consequences. This sheds new light to previous findings, suggesting that disruption of C-C motif ligand 5-CXCL4 interactions is a promising pharmacological approach to target atherosclerosis. 16, 50 We further show that the inhibition of cyclooxygenase by ASA effectively suppressed platelet-monocyte interactions in response to OxLDL and subsequently inhibited platelet-mediated OxLDL uptake by monocytes, whereas ASA had no effect on monocyte CD11b activation itself or OxLDL uptake by monocytes in the absence of platelets. Interestingly, the activation state of CD11b remained unaffected by ASA, whereas the percentage of PMAs decreased, indicating that CD11b is not important for platelet-monocyte interactions in this experimental setting.
Our findings are in line with previous in vitro and in vivo studies that showed an inhibitory effect of ASA on the amount of surface and soluble P-selectin, as well as on the level of circulating PMA in response to some platelet agonists and depending on the health status. 51, 52 ADP receptor antagonists are also frequently used antiplatelet therapeutics. Both purinergic receptors, P2Y1 and P2Y12, are differentially involved in prothrombotic platelet activation, as well as expression of platelet P-selectin, in response to various agonists 53, 54 and PMA formation. 55 P2Y1 and (to a lesser extent) P2Y12 inhibitors only antagonized plateletmediated interaction with monocytes and subsequent uptake of OxLDL but had no effect on monocyte-OxLDL interaction in the absence of platelets. These results indicate an involvement of TxA 2 and ADP as positive feedback mediators for OxLDL-induced platelet activation and subsequent OxLDL uptake by monocytes.
Platelet P-selectin binding to leukocyte PSGL-1 is known to result in the activation of the β2 integrin CD11b/CD18, which is required for firm adhesion of monocytes to and subsequent transmigration across the endothelium. 56 Indeed, we were able to show that in the presence of platelets OxLDL-mediated CD11b activation and OxLDL-induced monocyte transmigration through an endothelial monolayer was strongly enhanced in a P-selectin-PSGL-1-dependent fashion. Interestingly, blocking P-selectin decreased transmigration of monocytes even below OxLDL-stimulated monocytes in the absence of platelets, probably because of additional inhibition of endothelial P-selectin.
We further demonstrate in a peritonitis model for sterile inflammation using LDLR −/− mice that platelet depletion dramatically reduced the recruitment of monocyte-derived macrophages into the inflamed peritoneum. Platelet transfusion of OxLDL-treated but not unstimulated platelets was able to increase the number of peritoneal macrophages in platelet-depleted wild-type mice.
Moreover, we are the first to show that in response to OxLDL platelets actively contribute to foam cell formation in vivo because platelet depletion also resulted in a strong reduction of lipid accumulation in peritoneal macrophages in the thioglycollate-elicited peritonitis model in LDLR −/− mice. In vitro experiments performed with platelet-monocyte cocultures underlined our in vivo observations and confirmed and extended previous findings that activated platelets enhanced lipid accumulation, a central feature of foam cell formation. 13, 40, 57 In conclusion, our data provide first evidence that platelets are causally involved in lipid accumulation and in vivo transformation of monocyte-derived macrophages into lipid-laden foam cells by direct interaction with monocytes via P-selectin-PSGL-1.
Platelets are crucial players in the onset of atherosclerosis by facilitating leukocyte transmigration, 16, 32, 35, 58 and our results on platelet-induced lipid accumulation in monocytes provide a novel mechanism for how platelets contribute to the onset and progression of atherosclerosis and negatively regulate plaque stability.
In this study, we provide first evidence that platelets are causally involved in lipid accumulation and in vivo generation of monocyte-derived lipid-rich foam cells. By binding to platelet CD36, oxidized low-density lipoprotein mainly triggered the formation of complexes between platelets and CD16+ monocytes via P-selectin-PSGL-1 bridging. These platelet-monocyte aggregates showed an accelerated uptake of oxidized low-density lipoprotein, increased monocyte adhesive capacities, and enhanced transmigration through endothelial monolayers when compared with monocytes in the absence of platelets. Platelet CXC motif ligand 4 release and phagocytosis of platelets were responsible for the observed effects. Accordingly, the accelerating effects of platelets on monocyte uptake of oxidized low-density lipoprotein were diminished in the presence of CXC motif ligand 4 inhibitors, acetylsalicylic acid, and ADP receptor antagonists. In LDLR −/− mice platelet depletion resulted in strongly decreased macrophage recruitment into the sterile inflamed peritoneum and significantly attenuated foam cell formation. Thereby, our results shed new light on the accelerating effects of platelets in critical steps of atherogenesis.
Significance
